Today, Explained Adderall via Instagram
Jun 9, 2022
Rolf Winkler, a reporter for The Wall Street Journal, dives into the meteoric rise of Cerebral, a $5 billion online mental health platform, and its controversial prescription practices for ADHD medications. He discusses how pandemic-era regulations facilitated easy access to controlled substances and the ensuing Department of Justice investigation. Winkler addresses concerns about misleading advertising, the quality of diagnoses, and the ethical implications of rapid scaling in mental health care. Tune in for insights on accountability in telehealth!
AI Snips
Chapters
Transcript
Episode notes
Cerebral's Controversial Practices
- Cerebral, an online mental health company, faced controversy over its prescription practices.
- They offered quick access to controlled substances like Adderall, raising concerns about diagnoses and advertising.
Cerebral's Origins and Growth
- Cerebral launched in January 2020, aiming to prescribe medication for mental health conditions.
- The COVID-19 pandemic and relaxed telehealth regulations allowed them to prescribe controlled substances online.
Cerebral's Marketing and Business Model
- Cerebral's aggressive marketing involved social media ads and celebrity endorsements like Simone Biles.
- Their subscription model focuses on medication management, including prescription renewals, for various conditions.